» Articles » PMID: 34960608

Role of Damage-Associated Molecular Pattern/Cell Death Pathways in Vaccine-Induced Immunity

Overview
Journal Viruses
Publisher MDPI
Specialty Microbiology
Date 2021 Dec 28
PMID 34960608
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Immune responses induced by natural infection and vaccination are known to be initiated by the recognition of microbial patterns by cognate receptors, since microbes and most vaccine components contain pathogen-associated molecular patterns. Recent discoveries on the roles of damage-associated molecular patterns (DAMPs) and cell death in immunogenicity have improved our understanding of the mechanism underlying vaccine-induced immunity. DAMPs are usually immunologically inert, but can transform into alarming signals to activate the resting immune system in response to pathogenic infection, cellular stress and death, or tissue damage. The activation of DAMPs and cell death pathways can trigger local inflammation, occasionally mediating adaptive immunity, including antibody- and cell-mediated immune responses. Emerging evidence indicates that the components of vaccines and adjuvants induce immunogenicity via the stimulation of DAMP/cell death pathways. Furthermore, strategies for targeting this pathway to enhance immunogenicity are being investigated actively. In this review, we describe various DAMPs and focus on the roles of DAMP/cell death pathways in the context of vaccines for infectious diseases and cancer.

Citing Articles

Nano-bio-encapsulation of phyto-vaccines: a breakthrough in targeted cancer immunotherapy.

Ayyadurai P, Ragavendran C Mol Biol Rep. 2024; 52(1):58.

PMID: 39692899 DOI: 10.1007/s11033-024-10164-w.


Adjuvants influence the immune cell populations present at the injection site granuloma induced by whole-cell inactivated paratuberculosis vaccines in sheep.

Criado M, Reyes L, Marin J, Gutierrez-Exposito D, Zapico D, Espinosa J Front Vet Sci. 2024; 11:1284902.

PMID: 38352038 PMC: 10861745. DOI: 10.3389/fvets.2024.1284902.


Development of a Ready-to-Use-Type RNA Vaccine Carrier Based on an Intracellular Environment-Responsive Lipid-like Material with Immune-Activating Vitamin E Scaffolds.

Anindita J, Tanaka H, Oyama R, Hagiwara S, Shirane D, Taneichi S Pharmaceutics. 2023; 15(12).

PMID: 38140043 PMC: 10747879. DOI: 10.3390/pharmaceutics15122702.


Advances in tumor immunomodulation based on nanodrug delivery systems.

Wang B, Zhang Y, Yin X Front Immunol. 2023; 14:1297493.

PMID: 38106403 PMC: 10725201. DOI: 10.3389/fimmu.2023.1297493.


Knife's edge: Balancing immunogenicity and reactogenicity in mRNA vaccines.

Lee J, Woodruff M, Kim E, Nam J Exp Mol Med. 2023; 55(7):1305-1313.

PMID: 37430088 PMC: 10394010. DOI: 10.1038/s12276-023-00999-x.


References
1.
Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J . Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006; 440(7081):237-41. DOI: 10.1038/nature04516. View

2.
Yang H, Wang H, Chavan S, Andersson U . High Mobility Group Box Protein 1 (HMGB1): The Prototypical Endogenous Danger Molecule. Mol Med. 2015; 21 Suppl 1:S6-S12. PMC: 4661054. DOI: 10.2119/molmed.2015.00087. View

3.
Weinberger A . Gout, uric acid metabolism, and crystal-induced inflammation. Curr Opin Rheumatol. 1995; 7(4):359-63. DOI: 10.1097/00002281-199507000-00017. View

4.
Hampson A . Vaccines for pandemic influenza. The history of our current vaccines, their limitations and the requirements to deal with a pandemic threat. Ann Acad Med Singap. 2008; 37(6):510-7. View

5.
Walters A, Wang J, Al-Jamal K . Evaluation of cell surface reactive immuno-adjuvant in combination with immunogenic cell death inducing drug for in situ chemo-immunotherapy. J Control Release. 2020; 322:519-529. PMC: 7262586. DOI: 10.1016/j.jconrel.2020.03.029. View